<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00054340</url>
  </required_header>
  <id_info>
    <org_study_id>1723.00</org_study_id>
    <secondary_id>FHCRC-1723.00</secondary_id>
    <secondary_id>CDR0000270397</secondary_id>
    <nct_id>NCT00054340</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder</brief_title>
  <official_title>Conditioning With Targeted Busulfan, Cyclophosphamide and Thymoglobulin for Allogeneic Marrow or Peripheral Blood Stem Cell (PBSC) Transplantation for Myelodysplasia and Myeloproliferative Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Combining antithymocyte globulin with combination chemotherapy before donor&#xD;
      peripheral stem cell transplantation may reduce the chance of developing graft-versus-host&#xD;
      disease following transplantation.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to study the effectiveness of combining antithymocyte globulin with&#xD;
      busulfan and cyclophosphamide in reducing graft-versus-host disease in patients who are&#xD;
      undergoing donor stem cell transplantation for myelodysplastic syndrome or other&#xD;
      myeloproliferative disorder.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the incidence of acute graft-vs-host disease (GVHD) requiring therapy in&#xD;
           patients with myelodysplastic syndromes or myeloproliferative disorders treated with&#xD;
           busulfan, cyclophosphamide, and anti-thymocyte globulin prior to transplantation with&#xD;
           filgrastim (G-CSF)-mobilized peripheral blood stem cells (or bone marrow) from related&#xD;
           or unrelated donors.&#xD;
&#xD;
        -  Determine the incidence of relapse and relapse-free survival in patients treated with&#xD;
           this regimen.&#xD;
&#xD;
        -  Determine the incidence of non-relapse mortality by day 100 and 1 year&#xD;
           posttransplantation in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the incidence of Epstein-Barr virus reactivation, infections, and chronic GVHD&#xD;
           in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of anti-thymocyte globulin.&#xD;
&#xD;
        -  Conditioning and graft-vs-host disease (GVHD) prophylaxis: Patients receive oral&#xD;
           busulfan every 6 hours on days -7 to -4 (16 doses), cyclophosphamide IV on days -3 and&#xD;
           -2, and anti-thymocyte globulin IV over 3 hours on days -3, -2, and -1.&#xD;
&#xD;
      Cohorts of 15 patients receive adjusted doses of anti-thymocyte globulin to determine the&#xD;
      optimal dose at which Epstein-Barr virus (EBV) activation and GVHD are reduced. The optimal&#xD;
      dose is the dose at which 2 consecutive cohorts receive the same regimen.&#xD;
&#xD;
        -  Stem cell transplantation: Patients undergo peripheral blood stem cell (PBSC) or bone&#xD;
           marrow transplantation on day 0.&#xD;
&#xD;
        -  Posttransplantation GVHD prophylaxis: Patients receive cyclosporine IV continuously on&#xD;
           days -1 to 4 and then orally twice daily until day 180. Patients also receive&#xD;
           methotrexate on days 1, 3, 6, and 11.&#xD;
&#xD;
      Patients are followed every 6 months for 2 years and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30-45 patients will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Graft Versus Host Disease</condition>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Diseases</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of 1 of the following:&#xD;
&#xD;
               -  Myelodysplastic syndromes (including those that have evolved to acute myeloid&#xD;
                  leukemia)&#xD;
&#xD;
               -  Myeloproliferative disorders&#xD;
&#xD;
                    -  No chronic myelogenous leukemia&#xD;
&#xD;
               -  Other diseases eligible for conditioning with targeted busulfan,&#xD;
                  cyclophosphamide, and anti-thymocyte globulin that are not candidates for other&#xD;
                  studies&#xD;
&#xD;
          -  Available related or unrelated donor compatible for HLA-A, -B, -C, DRB1, and DQB1&#xD;
&#xD;
               -  A single allele mismatch at HLA-A, -B, -C, or DRB1 is allowed&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  65 and under&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  No severe limitation due to other diseases&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST no greater than 2 times normal&#xD;
&#xD;
          -  No hepatic disease&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 2 times upper limit of normal OR&#xD;
&#xD;
          -  Creatinine clearance at least 50% for age, gender, and weight&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No cardiac insufficiency requiring treatment&#xD;
&#xD;
          -  No symptomatic coronary artery disease&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No severe or mild hypoxemia&#xD;
&#xD;
               -  pO_2 at least 70 mm Hg and DLCO at least 70% of predicted OR&#xD;
&#xD;
               -  pO_2 at least 80 mm Hg and DLCO at least 60% of predicted&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No growth factors given posttransplantation concurrently with methotrexate&#xD;
             immunosuppression&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>H. Joachim Deeg, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <study_first_submitted>February 5, 2003</study_first_submitted>
  <study_first_submitted_qc>February 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2003</study_first_posted>
  <last_update_submitted>May 12, 2010</last_update_submitted>
  <last_update_submitted_qc>May 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2010</last_update_posted>
  <keyword>graft versus host disease</keyword>
  <keyword>polycythemia vera</keyword>
  <keyword>chronic idiopathic myelofibrosis</keyword>
  <keyword>essential thrombocythemia</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>untreated childhood acute myeloid leukemia and other myeloid malignancies</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>chronic eosinophilic leukemia</keyword>
  <keyword>chronic neutrophilic leukemia</keyword>
  <keyword>myelodysplastic/myeloproliferative disease, unclassifiable</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

